December Sees Three Milestones For ViiV’s Pipeline

R&D Chief Outlines 2 FDA Filings, 1 Expected Approval

ViiV Healthcare’s R&D head Kimberly Smith tells Scrip December will see the advancement of three key HIV therapies.

HIV
ViiV is a specialist HIV company • Source: Shutterstock

More from Business

More from Scrip